Even 1300 calories a day, as is offered on the 4 and 2 and 1 program, is extremely difficult for most people to sustain
In their trials, tirzepatide (Mounjaro) produced a higher average weight loss, about 20% of total body weight at the top dose, while orforglipron (Foundayo) produced about 12%, with some patients losing up to 15%
you tear the paper
Omega-3 fatty acids support cardiovascular health and have anti-inflammatory properties that may ease some gastrointestinal discomfort during treatment
The escalation schedule often follows this pattern: Week 1-4 : 0.25 mg once weekly Week 5-8 : 0.5 mg once weekly Week 9-12 : 1.0 mg once weekly Week 13-16 : 1.7 mg once weekly Week 17 and beyond : Up to 2.4 mg once weekly , which is the maximum dose for weight loss
Study design and endpoints This study reported secondary, OSA-specific outcomes from the SURMOUNT-OSA program